The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Alternative mechanisms of miR-34a regulation in cancer
Open accessAbstract
MicroRNA miR-34a is recognized as a master regulator of tumor suppression. The strategy of miR-34a replacement has been investigated in clinical trials as the first attempt of miRNA application in cancer treatment. However, emerging outcomes promote the re-evaluation of existing knowledge and urge the need for better understanding the complex biological role of miR-34a. The targets of miR-34a encompass numerous regulators of cancer cell proliferation, survival and resistance to therapy. MiR-34a expression is transcriptionally controlled by p53, a crucial tumor suppressor pathway, often disrupted in cancer. Moreover, miR-34a abundance is fine-tuned by context-dependent feedback loops. The function and effects of exogenously delivered or re-expressed miR-34a on the background of defective p53 therefore remain prominent issues in miR-34a based therapy. In this work, we review p53-independent mechanisms regulating the expression of miR-34a. Aside from molecules directly interacting with MIR34A promoter, processes affecting epigenetic regulation and miRNA maturation are discussed. Multiple mechanisms operate in the context of cancer-associated phenomena, such as aberrant oncogene signaling, EMT or inflammation. Since p53-dependent tumor-suppressive mechanisms are disturbed in a substantial proportion of malignancies, we summarize the effects of miR-34a modulation in cell and animal models in the clinically relevant context of disrupted or insufficient p53 function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Ng, W. L., Chen, G., Wang, M., wang, H., Story, M. D., Shay, J. W., Zhang, X., Wang, J., Amin, A. R. M. R., Hu, B., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.563 · Cited by 32
RetractedImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
MicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
Functions of DNA methylation: islands, start sites, gene bodies and beyond
Jones, P. A. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3230 · Cited by 6,061
DNA methylation: roles in mammalian development
Smith, Z. D., & Meissner, A. (2013) · Nature Reviews Genetics · doi:10.1038/nrg3354 · Cited by 3,045
The Microprocessor complex mediates the genesis of microRNAs
Gregory, R. I., Yan, K.-P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., & Shiekhattar, R. (2004) · Nature · doi:10.1038/nature03120 · Cited by 2,742
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · cited 1×
“Mechanisms of evasion from p53-mediated tumor suppression encompass selection of cancer cells harboring p53 mutations (nonsense or missense, eventually accompanied by a gain of function) or allelic loss, as well as inactivation by viral or cellular proteins.(19,36) An evolutionary conserved p53-binding site was identi…”
BackgroundTransactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Chang, T.-C., Wentzel, E. A., Kent, O. A., Ramachandran, K., Mullendore, M., Lee, K. H., Feldmann, G., Yamakuchi, M., Ferlito, M., Lowenstein, C. J., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.010 · Cited by 2,010
miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database
Chou, C.-H., Chang, N.-W., Shrestha, S., Hsu, S.-D., Lin, Y.-L., Lee, W.-H., Yang, C.-D., Hong, H.-C., Wei, T.-Y., Tu, S.-J., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1258 · Cited by 1,831
Tumor heterogeneity: Causes and consequences
Marusyk, A., & Polyak, K. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.11.002 · Cited by 1,602
The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44
Liu, C., Kelnar, K., Liu, B., Chen, X., Calhoun-Davis, T., Li, H., Patrawala, L., Yan, H., Jeter, C., Honorio, S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2284 · Cited by 1,400
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
miR-34a repression of SIRT1 regulates apoptosis
Yamakuchi, M., Ferlito, M., & Lowenstein, C. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801613105 · Cited by 1,342
Widespread microRNA repression by Myc contributes to tumorigenesis
Chang, T.-C., Yu, D., Lee, Y.-S., Wentzel, E. A., Arking, D. E., West, K. M., Dang, C. V., Thomas-Tikhonenko, A., & Mendell, J. T. (2008) · Nature Genetics · doi:10.1038/ng.2007.30 · Cited by 1,325
Modulation of microRNA processing by p53
Suzuki, H. I., Yamagata, K., Sugimoto, K., Iwamoto, T., Kato, S., & Miyazono, K. (2009) · Nature · doi:10.1038/nature08199 · Cited by 1,124
p53-Mediated Activation of miRNA34 Candidate Tumor-Suppressor Genes
Bommer, G. T., Gerin, I., Feng, Y., Kaczorowski, A. J., Kuick, R., Love, R. E., Zhai, Y., Giordano, T. J., Qin, Z. S., Moore, B. B., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.06.068 · Cited by 1,123
Tarasov, V., Jung, P., Verdoodt, B., Lodygin, D., Epanchintsev, A., Menssen, A., Meister, G., & Hermeking, H. (2007) · Cell Cycle · doi:10.4161/cc.6.13.4436 · Cited by 923
Tazawa, H., Tsuchiya, N., Izumiya, M., & Nakagama, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707351104 · Cited by 903
Beg, M. S., Brenner, A. J., Sachdev, J., Borad, M., Kang, Y.-K., Stoudemire, J., Smith, S., Bader, A. G., Kim, S., & Hong, D. S. (2017) · Investigational New Drugs · doi:10.1007/s10637-016-0407-y · Cited by 897
Characterization of microRNA expression profiles in normal human tissues.
Liang, Y., Ridzon, D., Wong, L., & Chen, C. (2007) · BMC Genomics · doi:10.1186/1471-2164-8-166 · Cited by 881
MicroRNA-34a regulates cardiac ageing and function.
Boon, R. A., Iekushi, K., Lechner, S., Seeger, T., Fischer, A., Heydt, S., Kaluza, D., Tréguer, K., Carmona, G., Bonauer, A., et al. (2013) · Nature · doi:10.1038/nature11919 · Cited by 821
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
Welch, C., Chen, Y., & Stallings, R. L. (2007) · Oncogene · doi:10.1038/sj.onc.1210293 · Cited by 805
OncomiR or Tumor Suppressor? The Duplicity of MicroRNAs in Cancer
Svoronos, A. A., Engelman, D. M., & Slack, F. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0359 · Cited by 791
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Lodygin, D., Tarasov, V., Epanchintsev, A., Berking, C., Knyazeva, T., Körner, H., Knyazev, P., Diebold, J., & Hermeking, H. (2008) · Cell Cycle · doi:10.4161/cc.7.16.6533 · Cited by 784
IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis
Rokavec, M., Öner, M. G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., Kaller, M., Horst, D., Ziegler, P. K., Schwitalla, S., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73531 · Cited by 753
miR-34 – a microRNA replacement therapy is headed to the clinic
Bader, A. G. (2012) · Frontiers in Genetics · doi:10.3389/fgene.2012.00120 · Cited by 728
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions
Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., & Hermeking, H. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18552 · Cited by 609
Gregory, P. A., Bracken, C. P., Smith, E., Bert, A. G., Wright, J. A., Roslan, S., Morris, M., Wyatt, L., Farshid, G., Lim, Y.-Y., et al. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e11-02-0103 · Cited by 552
Yang, P., Li, Q.-J., Feng, Y., Zhang, Y., Markowitz, G. J., Ning, S., Deng, Y., Zhao, J., Jiang, S., Yuan, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.07.023 · Cited by 536
Mir-34: A New Weapon Against Cancer?
Misso, G., Di Martino, M. T., De Rosa, G., Farooqi, A. A., Lombardi, A., Campani, V., Zarone, M. R., Gullà, A., Tagliaferri, P., Tassone, P., et al. (2014) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2014.47 · Cited by 498
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y.-L., Leung, M. L., El-Naggar, A., Creighton, C. J., Suraokar, M. B., et al. (2010) · Nature · doi:10.1038/nature09459 · Cited by 419
Smad Proteins Bind a Conserved RNA Sequence to Promote MicroRNA Maturation by Drosha
Davis, B. N., Hilyard, A. C., Nguyen, P. H., Lagna, G., & Hata, A. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.07.011 · Cited by 383
The p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC
Christoffersen, N. R., Shalgi, R., Frankel, L. B., Leucci, E., Lees, M., Klausen, M., Pilpel, Y., Nielsen, F. C., Oren, M., & Lund, A. H. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.109 · Cited by 352
p53 — a Jack of all trades but master of none
Junttila, M. R., & Evan, G. I. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2728 · Cited by 345
Hippo Signaling Regulates Microprocessor and Links Cell-Density-Dependent miRNA Biogenesis to Cancer
Mori, M., Triboulet, R., Mohseni, M., Schlegelmilch, K., Shrestha, K., Camargo, F. D., & Gregory, R. I. (2014) · Cell · doi:10.1016/j.cell.2013.12.043 · Cited by 335
p63 and p73, the ancestors of p53
Dotsch, V., Bernassola, F., Coutandin, D., Candi, E., & Melino, G. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a004887 · Cited by 326
Wang, X., Li, J., Dong, K., Lin, F., Long, M., Ouyang, Y., Wei, J., Chen, X., Weng, Y., He, T., et al. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2014.12.003 · Cited by 313
Vogt, M., Munding, J., Grüner, M., Liffers, S.-T., Verdoodt, B., Hauk, J., Steinstraesser, L., Tannapfel, A., & Hermeking, H. (2011) · Virchows Archiv · doi:10.1007/s00428-010-1030-5 · Cited by 309
Frequent Downregulation of miR-34 Family in Human Ovarian Cancers
Corney, D. C., Hwang, C.-I., Matoso, A., Vogt, M., Flesken-Nikitin, A., Godwin, A. K., Kamat, A. A., Sood, A. K., Ellenson, L. H., Hermeking, H., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2642 · Cited by 308
A positive feedback between p53 and miR-34 miRNAs mediates tumor suppression
Okada, N., Lin, C.-P., Ribeiro, M. C., Biton, A., Lai, G., He, X., Bu, P., Vogel, H., Jablons, D. M., Keller, A. C., et al. (2014) · Genes & Development · doi:10.1101/gad.233585.113 · Cited by 297
MicroRNA-34a: a potential therapeutic target in human cancer
Li, X. J., Ren, Z. J., & Tang, J. H. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.270 · Cited by 287
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Zenz, T., Mohr, J., Eldering, E., Kater, A. P., Bühler, A., Kienle, D., Winkler, D., Dürig, J., van Oers, M. H. J., Mertens, D., et al. (2009) · Blood · doi:10.1182/blood-2008-08-172254 · Cited by 273
Wu, J., Bao, J., Kim, M., Yuan, S., Tang, C., Zheng, H., Mastick, G. S., Xu, C., & Yan, W. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407777111 · Cited by 266
Nalls, D., Tang, S.-N., Rodova, M., Srivastava, R. K., & Shankar, S. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024099 · Cited by 256
Agostini, M., & Knight, R. A. (2014) · Oncotarget · doi:10.18632/oncotarget.1825 · Cited by 254
Kasinski, A. L., & Slack, F. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2001 · Cited by 242
Di Martino, M. T., Leone, E., Amodio, N., Foresta, U., Lionetti, M., Pitari, M. R., Cantafio, M. E. G., Gullà, A., Conforti, F., Morelli, E., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1708 · Cited by 239
Rao, D. S., O'Connell, R. M., Chaudhuri, A. A., Garcia-Flores, Y., Geiger, T. L., & Baltimore, D. (2010) · Immunity · doi:10.1016/j.immuni.2010.06.013 · Cited by 234
miR-34/449 miRNAs are required for motile ciliogenesis by repressing CP110
Song, R., Walentek, P., Sponer, N., Klimke, A., Lee, J. S., Dixon, G., Harland, R., Wan, Y., Lishko, P., Lize, M., et al. (2014) · Nature · doi:10.1038/nature13413 · Cited by 228
Misinterpreting the Therapeutic Effects of Small Interfering RNA Caused by Immune Stimulation
Robbins, M., Judge, A., Ambegia, E., Choi, C., Yaworski, E., Palmer, L., McClintock, K., & MacLachlan, I. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.131 · Cited by 220
miR-34 and p53: New Insights into a Complex Functional Relationship
Navarro, F., & Lieberman, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132767 · Cited by 202
Intact p53-Dependent Responses in miR-34–Deficient Mice
Concepcion, C. P., Han, Y.-C., Mu, P., Bonetti, C., Yao, E., D'Andrea, A., Vidigal, J. A., Maughan, W. P., Ogrodowski, P., & Ventura, A. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002797 · Cited by 197
The Quest for the 1p36 Tumor Suppressor
Bagchi, A., & Mills, A. A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2095 · Cited by 196
BRCA1 regulates microRNA biogenesis via the DROSHA microprocessor complex
Kawai, S., & Amano, A. (2012) · Journal of Cell Biology · doi:10.1083/jcb.201110008 · Cited by 182
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
Mraz, M., Malinova, K., Kotaskova, J., Pavlova, S., Tichy, B., Malcikova, J., Stano Kozubik, K., Smardova, J., Brychtova, Y., Doubek, M., et al. (2009) · Leukemia · doi:10.1038/leu.2008.377 · Cited by 177
Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets
Agostini, M., Tucci, P., Killick, R., Candi, E., Sayan, B. S., Rivetti di val Cervo, P., Nicotera, P., McKeon, F., Knight, R. A., Mak, T. W., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1112061109 · Cited by 171
MicroRNA Processing and Human Cancer
Ohtsuka, M., Ling, H., Doki, Y., Mori, M., & Calin, G. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4081651 · Cited by 170
Du, R., Sun, W., Xia, L., Zhao, A., Yu, Y., Zhao, L., Wang, H., Huang, C., & Sun, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030771 · Cited by 169
Craig, V. J., Cogliatti, S. B., Imig, J., Renner, C., Neuenschwander, S., Rehrauer, H., Schlapbach, R., Dirnhofer, S., Tzankov, A., & Müller, A. (2011) · Blood · doi:10.1182/blood-2010-10-312231 · Cited by 166
SNAIL and miR‐34a feed‐forward regulation of ZNF281/ZBP99 promotes epithelial–mesenchymal transition
Hahn, S., Jackstadt, R., Siemens, H., Hünten, S., & Hermeking, H. (2013) · The EMBO Journal · doi:10.1038/emboj.2013.236 · Cited by 165
ZEB1 drives prometastatic actin cytoskeletal remodeling by downregulating miR-34a expression
Ahn, Y., Gibbons, D. L., Chakravarti, D., Creighton, C. J., Rizvi, Z. H., Adams, H. P., Pertsemlidis, A., Gregory, P. A., Wright, J. A., Goodall, G. J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63608 · Cited by 162
Functional elucidation of MiR-34 in osteosarcoma cells and primary tumor samples
He, C., Xiong, J., Xu, X., Lu, W. D., Liu, L., Xiao, D., & Wang, D. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.07.101 · Cited by 148
Stahlhut, C. E., & Slack, F. J. (2015) · Cell Cycle · doi:10.1080/15384101.2014.1003008 · Cited by 148
Epigenetic Regulation of miR-34a Expression in Alcoholic Liver Injury
Meng, F., Glaser, S. S., Francis, H., Yang, F., Han, Y., Stokes, A., Staloch, D. A., McCarra, J., Liu, J., Venter, J. K., et al. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2012.06.010 · Cited by 144
Siemens, H., Neumann, J. H. L., Jackstadt, R., Mansmann, U., Horst, D. A., Kirchner, T., & Hermeking, H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1703 · Cited by 144
Baer, C. R., Claus, R., Frenzel, L. P., Zucknick, M., Park, Y. J., Gu, L., Weichenhan, D., Fischer, M., Pallasch, C. P., Herpel, E., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0803 · Cited by 138
Antonini, D., Russo, M. T., Rosa, L. D., Gorrese, M., Vecchio, L. D., & Missero, C. (2010) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.438 · Cited by 126
Hanrahan, K., O’Neill, A., Prencipe, M., Bugler, J., Murphy, L., Fabre, A., Puhr, M., Čulig, Z., Murphy, K., & Watson, R. W. G. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12030 · Cited by 126
Dong, P., Xiong, Y., Watari, H., Hanley, S. J. B., Konno, Y., Ihira, K., Yamada, T., 工藤, 正., Yue, J., & Sakuragi, N. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0415-y · Cited by 123
Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer.
Mirchandani, D., Zheng, J., Miller, G. J., Ghosh, A. K., Shibata, D. K., Côté, R. J., & Roy‐Burman, P. (1995) · Europe PMC (PubMed Central) · Cited by 120
Xu, X., Chen, W., Miao, R., Zhou, Y., Wang, Z., Zhang, L., Wan, Y., Dong, Y., Qu, K., & Liu, C. (2015) · Oncotarget · doi:10.18632/oncotarget.2905 · Cited by 115
MicroRNA-34a: A Novel Tumor Suppressor in p53-mutant Glioma Cell Line U251
Luan, S., Sun, L., & Huang, F. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.02.007 · Cited by 113
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity
Gurtner, A., Falcone, E., Garibaldi, F., & Piaggio, G. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-016-0319-x · Cited by 113
p53 and miR-34a Feedback Promotes Lung Epithelial Injury and Pulmonary Fibrosis
Shetty, S. K., Tiwari, N., Marudamuthu, A. S., Puthusseri, B., Bhandary, Y. P., Fu, J., Levin, J. L., Idell, S., & Shetty, S. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.12.020 · Cited by 112
Cheng, C.-Y., Hwang, C., Corney, D. C., Flesken‐Nikitin, A., Jiang, L., Öner, M. G., Munroe, R. J., Schimenti, J. C., Hermeking, H., & Nikitin, A. Y. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.023 · Cited by 110
Vinall, R., Ripoll, A., Wang, S., Pan, C., & White, R. D. D. (2011) · International Journal of Cancer · doi:10.1002/ijc.26256 · Cited by 110
Jiang, P., Liu, R., Zheng, Y., Liu, X., Chang, L., Xiong, S., & Chu, Y. (2012) · Experimental Cell Research · doi:10.1016/j.yexcr.2012.03.018 · Cited by 108
Transcriptional activation of microRNA-34a by NF-kappa B in human esophageal cancer cells
Li, J., Wang, K., Chen, X., Meng, H., Song, M., Wang, Y., Xu, X., & Bai, Y. (2012) · BMC Molecular Biology · doi:10.1186/1471-2199-13-4 · Cited by 106
Peurala, H., Greco, D., Heikkinen, T., Kaur, S., Bártková, J., Jamshidi, M., Aittomäki, K., Heikkilä, P., Bartek, J., Blomqvist, C., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026122 · Cited by 101
Qiao, P., Li, G., Bi, W., Yang, L., Yao, L., & Wu, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1359-x · Cited by 93
MicroRNA-34a Modulates MDM4 Expression via a Target Site in the Open Reading Frame
Mandke, P., Wyatt, N., Fraser, J., Bates, B., Berberich, S. J., & Markey, M. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042034 · Cited by 92
Zhou, J., Chen, X., Zhao, J., Bao, Z., Chen, X., Zhang, P., Liu, Z.-F., & Zhou, J. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.06.010 · Cited by 84
The diagnostic role of microRNA-34a in breast cancer: a systematic review and meta-analysis
İmani, S., Zhang, X., Hosseinifard, H., Fu, S., & Fu, J. (2017) · Oncotarget · doi:10.18632/oncotarget.15520 · Cited by 79
Knouf, E. C., Garg, K. S., Arroyo, J. D., Correa, Y., Sarkar, D., Parkin, R. K., Wurz, K., O'Briant, K. C., Godwin, A. K., Urban, N. D., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr731 · Cited by 74
Shear-sensitive MicroRNA-34a Modulates Flow-dependent Regulation of Endothelial Inflammation
Fan, W., Fang, R., Wu, X., Liu, J., Feng, M., Dai, G., Chen, G., & Wu, G. (2014) · Journal of Cell Science · doi:10.1242/jcs.154252 · Cited by 72
microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review)
Yang (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.970 · Cited by 72
Multiple p53-independent gene silencing mechanisms define the cellular response to p53 activation
París, R., Henry, R. E., Stephens, S. J., McBryde, M., & Espinosa, J. M. (2008) · Cell Cycle · doi:10.4161/cc.6420 · Cited by 70
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
Dijkstra, M. K., van Lom, K., Tielemans, D., Elstrodt, F., Langerak, A. W., Veer, M. B. V., & Jongen‐Lavrencic, M. (2008) · Leukemia · doi:10.1038/leu.2008.264 · Cited by 63
TP53-independent Function of miR-34a via HDAC1 and p21CIP1/WAF1
Zhao, J. Y., Lammers, P., Torrance, C. J., & Bader, A. G. (2013) · Molecular Therapy · doi:10.1038/mt.2013.148 · Cited by 62
Hiyoshi, Y., Schetter, A. J., Okayama, H., Inamura, K., Anami, K., Nguyen, G. H., Horikawa, I., Hawkes, J. E., Bowman, E. D., Leung, S. Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124899 · Cited by 61
Synthetic pre-microRNAs reveal dual-strand activity of miR-34a on TNF-α
Guennewig, B., Roos, M. M., Dogar, A. M., Gebert, L. F. R., Zagalak, J. A., Vongrad, V., Metzner, K. J., & Hall, J. (2013) · RNA · doi:10.1261/rna.038968.113 · Cited by 58
Role of Inflammation-Associated Microenvironment in Tumorigenesis and Metastasis
Gao, F., Liang, B., Reddy, S. T., et al. (2014) · Current Cancer Drug Targets · doi:10.2174/15680096113136660107 · Cited by 56
Mutant p53 inhibits miRNA biogenesis by interfering with the microprocessor complex
Garibaldi, F., Falcone, E., Trisciuoglio, D., Colombo, T., Lisek, K., Walerych, D., Sal, G. D., Paci, P., Bossi, G., Piaggio, G., et al. (2016) · Oncogene · doi:10.1038/onc.2016.51 · Cited by 53
microRNA-34a Sensitizes Lung Cancer Cell Lines to DDP Treatment Independent of p53 Status
Wang, X., Dong, K., Gao, P., Long, M., Fang, L., Weng, Y., Ouyang, Y., Ren, J.-H., & Zhang, H. (2012) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2012.1218 · Cited by 51
Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide
Mathé, E. A., Nguyen, G. H., Funamizu, N., He, P., Moake, M. M., Croce, C. M., & Hussain, S. P. (2011) · International Journal of Cancer · doi:10.1002/ijc.26403 · Cited by 50
MicroRNA-34a Enhances T Cell Activation by Targeting Diacylglycerol Kinase ζ
Shin, J., Xie, D., & Zhong, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077983 · Cited by 49
Identification of targets of tumor suppressor microRNA-34a using a reporter library system
Ito, Y., Inoue, A., Seers, T., Hato, Y., Igarashi, A., Toyama, T., Taganov, K. D., Boldin, M., & Asahara, H. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620019114 · Cited by 47
Wang, L., Yu, J., Xu, J., Zheng, C., Li, X., & Du, J. (2014) · Gene · doi:10.1016/j.gene.2014.10.032 · Cited by 42
Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells
Cho, C.-Y., Huang, J.-S., Shiah, S., Chung, S.-Y., Lay, J., Yang, Y.-Y., Lai, G., Cheng, A., Chen, L., & Chuang, S. (2015) · RNA · doi:10.1261/rna.052571.115 · Cited by 42
Dogar, A. M., Towbin, H., & Hall, J. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.208652 · Cited by 31
Zhao, L., Mao, Y., Zhao, Y., & He, Y. (2016) · Scientific Reports · doi:10.1038/srep32739 · Cited by 29
Lu, X., Chen, K., Liang, H., Li, Z., Zou, X., Luo, H., Guo, W., & Xu, L. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.005 · Cited by 19
miR-34a is essential for p19Arf-driven cell cycle arrest
Iqbal, N. S., Mei, J., Liu, J., & Skapek, S. X. (2014) · Cell Cycle · doi:10.4161/cc.27725 · Cited by 17
SIRT1 modulates miRNA processing defects in p53-mutated human keratinocytes
Herbert, K. J., Cook, A. L., & Snow, E. T. (2014) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2014.01.008 · Cited by 12
Micro(mi) RNA-34a targets protein phosphatase (PP)1γ to regulate DNA damage tolerance
Takeda, Y., & Venkitaraman, A. R. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1064202 · Cited by 9
Cited by
Therapeutic advances of miRNAs: A preclinical and clinical update
Chakraborty, C., Sharma, A. R., Sharma, G., & Lee, S.-S. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2020.08.012 · Cited by 402
Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches
Tufail, M., Jiang, C.-H., & Li, N. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02280-1 · Cited by 363
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
Cavalcante, M. B., Saccon, T. D., Nunes, A. D. C., Kirkland, J. L., Tchkonia, T., Schneider, A., & Masternak, M. M. (2020) · Aging · doi:10.18632/aging.102772 · Cited by 80
Metadata
- Authors
- Slabáková, E., Culig, Z., Remšík, J., & Souček, K.
- Venue
- Cell Death & Disease
- Published
- 2017-10-12
- Volume
- 8
- Issue
- 10
- Pages
- e3100-e3100
- ISSN
- 2041-4889 (ISSN-L)
- OpenAlex
- W2763422050
- Cited by
- 264
- References
- 109
- FWCI
- 8.11
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.